Expertise in
4
conditions

Dr. Pritesh Patel

Radiology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 2 Trials
18 Years of Experience
Expertise in
4
conditions
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pritesh Patel is a Radiologist in Milwaukee, Wisconsin. Dr. Patel has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Gas Bloat Syndrome, Ascites, Visceromegaly, Intestinal Pseudo-Obstruction, and Tissue Biopsy.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2008
Specialties
Radiology
Licenses
Diagnostic Radiology in IL
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Community Memorial Hospital
Froedtert Community Hospital
St Josephs Community Hospital West Bend
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226
Other Locations
THE MEDICAL COLLEGE OF WISCONSIN INC
2315 E Moreland Blvd, Suite 100, Waukesha, WI 53186
THE MEDICAL COLLEGE OF WISCONSIN INC
W180n8085 Town Hall Rd, Suite 301, Menomonee Falls, WI 53051
THE MEDICAL COLLEGE OF WISCONSIN INC
1155 N Mayfair Rd, Fl 2, Milwaukee, WI 53226
THE MEDICAL COLLEGE OF WISCONSIN INC
W180 N8065 Town Hall Rd, Menomonee Falls, WI 53051
FROEDTERT ANDTHE MEDICAL COLLEGE OF WISCONSIN COMMUNITY PHYSICIANS INC
W168n11237 Western Ave, Germantown, WI 53022
FROEDTERT ANDTHE MEDICAL COLLEGE OF WISCONSIN COMMUNITY PHYSICIANS INC
1700 W Paradise Dr, West Bend, WI 53095
THE MEDICAL COLLEGE OF WISCONSIN INC
3200 Pleasant Valley Rd, West Bend, WI 53095
FROEDTERT ANDTHE MEDICAL COLLEGE OF WISCONSIN COMMUNITY PHYSICIANS INC
4805 S Moorland Rd, New Berlin, WI 53151
THE MEDICAL COLLEGE OF WISCONSIN INC
3212 Pleasant Valley Rd, West Bend, WI 53095

Additional Areas of Focus

Dr. Patel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide
Study Phase: Phase 3
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)
Enrollment Status: Recruiting
Publish Date: December 13, 2024
Intervention Type: Device, Drug, Other
Study Drugs: Fludarabine, Cyclophosphamide, Tacrolimus
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma
BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 13, 2024
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Melphalan, Filgrastim (G-CSF)
Study Phase: Phase 1
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve
Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve
Enrollment Status: Completed
Publish Date: September 23, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

77 Total Publications

Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.
Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.
Journal: Haematologica
Published: February 04, 2025
Similar Doctors
Experienced in Neurofibromatosis Type 1 (NF1)
Dr. Teresa Kelly
Radiology | Pediatrics | Pediatric Radiology
Experienced in Neurofibromatosis Type 1 (NF1)
Dr. Teresa Kelly
Radiology | Pediatrics | Pediatric Radiology

Advanced Radiology Services PC

670 Vernon Pl, 
Elm Grove, WI 
 (3.3 miles away)
616-363-7272
Languages Spoken:
English
See accepted insurances

Teresa Kelly is a Radiologist and a Pediatrics provider in Elm Grove, Wisconsin. Dr. Kelly is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are PHACE Syndrome, Arachnoid Cysts, Choroid Plexus Cyst, and Familial Porencephaly.

Advanced in Neurofibromatosis Type 1 (NF1)
Dr. Melissa Dubois
Radiology
Advanced in Neurofibromatosis Type 1 (NF1)
Dr. Melissa Dubois
Radiology

The Medical College Of Wisconsin Inc

8700 Watertown Plank Rd, 
Milwaukee, WI 
 (0.1 miles away)
414-805-7100
Languages Spoken:
English
See accepted insurances

Melissa Dubois is a Radiologist in Milwaukee, Wisconsin. Dr. Dubois is rated as an Advanced provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). Her top areas of expertise are Calcium Pyrophosphate Arthritis, Gas Bloat Syndrome, Caffey Disease, and Tenosynovitis.

Distinguished in Neurofibromatosis Type 1 (NF1)
Dr. Keith Baynes
Radiology | Radiation Oncology
Distinguished in Neurofibromatosis Type 1 (NF1)
Dr. Keith Baynes
Radiology | Radiation Oncology

The Medical College Of Wisconsin Inc

10000 W Bluemound Rd, 
Wauwatosa, WI 
 (1.0 miles away)
414-454-8000
Languages Spoken:
English

Keith Baynes is a Radiologist and a Radiation Oncologist in Wauwatosa, Wisconsin. Dr. Baynes is rated as a Distinguished provider by MediFind in the treatment of Neurofibromatosis Type 1 (NF1). His top areas of expertise are Melorheostosis, Melorheostosis with Osteopoikilosis, Osteopenia, and Calcium Pyrophosphate Arthritis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile